別紙４
研究成果の刊行に関する一覧表
書籍
著者氏名 論文タイトル名 書籍全体の
編集者名
書 籍 名 出版社名 出版地 出版年 ページ
和田 隆志 急速進行性腎炎症 候群（ANCA関連腎 炎を含む）
福井次矢・
高木誠・小 室一成
今日の治療指 針 2020
医学書院 東京 2020 602-604
古澤嘉彦 神経疾患における 患者レジストリの 意義と可能性
水 澤 英 洋/ 古澤嘉彦
脳神経内科 科 学 評 論 社
東京 2020 265-270
福井亮 難病データベース の現状と展望
内田章義 腎臓内科 科 学 評 論 社
東京都 2021年 1月
120-128
井田博幸 小児慢性特定疾患 児童成人移行期支 援モデル事業
医学のあゆみ 医 歯 薬 出 版㈱
平 成3 0 年
901-906
井田博幸 Gaucher病に対す る基質合成抑制療 法
小児内科 東 京 医 学 社
平 成3 0 年
1557-158 0
井田博幸 ライソゾーム病の 基礎と臨床
医学のあゆみ 医 歯 薬 出 版㈱
平 成3 0 年
31-36
井田博幸 酵素補充療法の有 効性と限界
日本臨床 日 本 臨 床 社
令 和 元 年
1326-133 1
井田博幸 リピドーシス 新臨床内科学 第10版
医学書院 令 和 2 年
780-784
井田博幸 先天代謝異常 Gau cher病
今日の小児治 療指針 第17 版
医学書院 令 和 2 年
199-200
寒川真、
楠 進。
補体を標的とした 神経免疫疾患の新 規治療
鈴木則宏 他 Annual Review 神経2019
中 外 医 学 社
東京 2019 113-122
楠 進 神経筋疾患におけ る糖脂質抗体測定
鈴木則宏 他 Annual Review 神経2020
中 外 医 学 社
東京 2020 300-305
秋丸裕司、
坂手龍一、
吉野満昭、
木村友則
指定難病の臨床調 査個人票のデータ ベース活用
腎臓内科編 集委員会
腎臓内科 科 学 評 論 社
日本 2020 12(5),58 9-600
秋丸裕司、
乾和歌子、
村井英継
指定難病の臨床調 査個人票とのデー タベース連携
脳神経内科 編集委員会
脳神経内科 科 学 評 論 社
日本 2020 92(3),33 2-339
大竹 明 小 児の難病 と｢AL A｣
北尾吉孝＋
｢A L Aの 未 来 ｣ を 考 え る会
A L Aが 創 る 未 来．｢生命の根 源 物 質 ｣ で バ イオと医療・
健康に貢献す る．
P H P研 究 所
東京 2020 177-199
村山 圭,小 坂 仁,三牧 将和
ミトコンドリアと 病気
村山 圭,小 坂 仁,三牧 将和
遺伝医学MOOK メ デ ィ カ ルドゥ
東京 2020 172-176
村山 圭 ミトコンドリア異 常症
水口 雅，市 橋 光，崎山 弘，伊藤 秀一
今日の小児診 療指針
医学書院 東京 2020 194-195
山野嘉久. HTLV-1関連脊髄症
（HAM）の新たな診 察ガイドライン.
鈴 木 則 宏, 荒 木 信,宇 川 義 一,桑 原 聡,塩 川 芳昭
Annual Review 神経2020
中 外 医 学 社
東京 2020 131-136
山野嘉久, 他：「HTL V-1関連脊 髄症（HAM）
診 療 ガ イ ドライン2 019」作成 委員会.
HTLV-1関連脊髄症
（HAM）診療ガイド ライン2019.
「HTLV-1関 連脊髄症（H AM）診療ガ イドライン 2019」作成 委員会
HTLV-1関連脊 髄症（HAM）診 療ガイドライ ン2019.
南江堂 東京 2019 1-181
山野嘉久. HTLV-1関連脊髄症 [指定難病26]
水澤英洋、
五十嵐 隆、
北川泰久、
高橋和久、
弓倉 整
指定難病ペデ ィア2019
診 断 と 治 療社
東京 2019 95-97
山野嘉久. HTLV-1関連脊髄症 南学正臣 内科学書 改 訂第9版
中山書店 東京 2019 386-387
山野嘉久. 痙性対麻痺（HAMを 含む）.
福 井 次 矢, 高木誠, 小 室一成
今日の治療方 針 2020年度 版
医学書院 東京 2020 62:
980-981 山野嘉久. H T L V - 1関 連 脊 髄
症.
永井良三 今日の診断指 針 第8版 ポ ケット判
医学書院 東京 2020 593-596
佐 々 木 秀 直、渡辺宏 久、下畑享 良、日本神 経 学 会 運 動 失 調 症 セ ク シ ョ ン
運動失調症の呼吸 管理
小林弘祐 標準的医療説 明の手順書
内 科 系 学 会 社 会 保 険料連合
東京 2019 128-133
佐藤晃一、
原章規、和 田隆志
腎臓障害に関連す る指定難病の動向
腎臓内科 科 学 評 論 社
東京 2021 136-143
雑誌
発表者氏名 論文タイトル名 発表誌名 巻号 ページ 出版年 Hara A, Wada T, Sa
da KE, Amano K, Do bashi H, Harigai M, Takasaki Y, Yamad a H, Hasegawa H, H ayashi T, Fujimoto S, Muso E, Kawakam i T, Homma S, Yosh ida M, Hirahashi J, Ogawa N, Ito S, M akino H, Arimura Y;
Research Committe e on Intractable V asculitides and th e Strategic Study Group to Establish the Evidence for I ntractable Vasculi tis Guideline.
Risk Factors for Relapse of Antineutrophil Cytopl asmic Antibody-associate d Vasculitis in Japan: A Nationwide, Prospective Cohort Study.
J Rheumatol 45(4) 521-528 2018
Yamamoto R, Imai E, Maruyama S, Yokoy ama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Taked a A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsu ruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Na gai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Narus e T, Fukami K, Nis hino T, Sobajima H, Tanaka S, Akahori T, Ito T, Yoshio T, Katafuchi R, Fuji moto S, Okada H, I shimura E, Kazama JJ, Hiromura K, Mi mura T, Suzuki S, Saka Y, Sofue T, S uzuki Y, Shibagaki Y, Kitagawa K, Mor ozumi K, Fujita Y, Mizutani M, Shigem atsu T, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.
Regional variations in i mmunosuppressive therapy in patients with primar y nephrotic syndrome: th e Japan nephrotic syndro me cohort study.
Clin Exp Ne phrol
22(6) 1266-1280 2018
Harigai M, Nagasak a K, Amano K, Band o M, Dobashi H, Ka wakami T, Kishibe K, Murakawa Y, Usu i J, Wada T, Tanak a E, Nango E, Naka yama T, Tsutsumino M, Yamagata K, Hom ma S, Arimua Y.
2017 Clinical practice g uidelines of the Japan R esearch Committee of the Ministry of Health, Labo ur, and Welfare for Intr actable Vasculitis for t he management of ANCA-as sociated vasculitis.
Mod Rheumat ol
29(1) 20-30 2018
Kanda E, Kashihara N, Matsushita K, U sui T, Okada H, Is eki K, Mikami K, T anaka T, Wada T, W atada H, Ueki K, N angaku M; Research Working Group for Establishing Guide lines for Clinical Evaluation of Chro nic Kidney Disease.
Guidelines for clinical evaluation of chronic ki dney disease : AMED rese arch on regulatory scien ce of pharmaceuticals an d medical devices.
Clin Exp Ne phrol
22(6) 1446-1475 2018
Kikuchi K, Saigusa D, Kanemitsu Y, Ma tsumoto Y, Thanai P, Suzuki N, Mise K, Yamaguchi H, Na kamura T, Asaji K, Mukawa C, Tsukamot o H, Sato T, Oikaw a Y, Iwasaki T, Oe Y, Tsukimi T, Fuku da NN, Ho HJ, Nant o-Hara F, Ogura J, Saito R, Nagao S, Ohsaki Y, Shimada S, Suzuki T, Toyoh ara T, Mishima E, Shima H, Akiyama Y, Akiyama Y, Ichijo M, Matsuhashi T, M atsuo A, Ogata Y, Yang CC, Suzuki C, Breeggemann MC, He ymann J, Shimizu M, Ogawa S, Takahash i N, Suzuki T, Owa da Y, Kure S, Mano N, Soga T, Wada T, Kopp JB, Fukuda S, Hozawa A, Yamamoto M, Ito S, Wada J, Tomioka Y, Abe T.
Gut microbiome-derived p henyl sulfate contribute s to albuminuria in diab etic kidney disease.
Nat Commun 10(1) 1835 2019
Isobe M, Amano K, Arimura Y, Ishizu A, Ito S, Kaname S, Kobayashi S, Kom agata Y, Komuro I, Komori K, Takahash i K, Tanemoto K, Hasegawa H, Hariga i M, Fujimoto S, M iyazaki T, Miyata T, Yamada H, Yoshi da A, Wada T, Inou e Y, Uchida A. H, Ota H, Okazaki T, Onimaru M, Kawakam i T, Kinouchi R, K urata A, Kosuge H, Sada K, Shigematsu K, Suematsu E, Sue yoshi E, Sugihara T, Sugiyama H, Tak eno M, Tamura N, T sutsumino M, Dobas hi H, Nakaoka Y, N agasaka K, Maejim a Y, Yoshifuji H, Watanabe Y, Ozaki S, Kimura T, Shig ematsu H, Yamauchi -Takihara K, Muroh ara T, Momomura S, on behalf of the J CS Joint Working G roup
JCS 2017 Guideline on Ma nagement of Vasculitis S yndrome ― Digest Versio n ―
Circ J 84(2) 299-359 2020
Tran TTT, Hara A, Kitagawa K, Kitaji ma S, Toyama T, Iw ata Y, Sakai N, Sh imizu M, Kaneko S, Furuichi K, Wada T.
Relationship between aut oantibodies to erythropo ietin receptor and renal outcome in patients with anti-neutrophil cytoplas mic antibody-associated vasculitis.
Biomarkers 25(2) 194-200 2020
Yamamoto R, Imai E, Maruyama S, Yokoy ama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Taked a A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsu ruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Na gai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Narus e T, Nishino T, So bajima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuch i R, Fujimoto S, O kada H, Ishimura E, Kazama JJ, Hiromu ra K, Mimura T, Su zuki S, Saka Y, So fue T, Suzuki Y, S hibagaki Y, Kitaga wa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, K ashihara N, Sato H, Matsuo S, Narita I, Isaka Y.
Incidence of remission a nd relapse of proteinuri a, end-stage kidney dise ase, mortality, and majo r outcomes in primary ne phrotic syndrome: the Ja pan Nephrotic Syndrome C ohort Study (JNSCS).
Clin Exp Ne phrol
24(6) 526-540 2020
北川清樹・和田隆志 血漿交換療法の適応と現状 日本医師会 雑誌
148(3) 447-451 2019
Yamamoto R, Imai E, Maruyama S, Yokoy ama H, Sugiyama H, Nitta K, Tsukamoto T, Uchida S, Taked a A, Sato T, Wada T, Hayashi H, Akai Y, Fukunaga M, Tsu ruya K, Masutani K, Konta T, Shoji T, Hiramatsu T, Goto S, Tamai H, Nishio S, Shirasaki A, Na gai K, Yamagata K, Hasegawa H, Yasuda H, Ichida S, Narus e T, Nishino T, So bajima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuch i R, Fujimoto S, O kada H, Ishimura E, Kazama JJ, Hiromu ra K, Mimura T, Su zuki S, Saka Y, So fue T, Suzuki Y, S hibagaki Y, Kitaga wa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, K ashihara N, Sato H, Matsuo S, Narita I, Isaka Y.
Incidence of remission a nd relapse of proteinuri a, end-stage kidney dise ase, mortality, and majo r outcomes in primary ne phrotic syndrome: the Ja pan Nephrotic Syndrome C ohort Study (JNSCS).
Clin Exp Ne phrol
24(6) 526-540 2020
Nakagawa N, Sofue T, Kanda E, Nagasu H, Matsushita K, N angaku M, Maruyama S, Wada T, Terada Y, Yamagata K, Nar ita I, Yanagita M, Sugiyama H, Shigem atsu T, Ito T, Tam ura K, Isaka Y, Ok ada H, Tsuruya K, Yokoyama H, Nakash ima N, Kataoka H, Ohe K, Okada M, Ka shihara N.
J-CKD-DB: a nationwide m ulticentre electronic he alth record-based chroni c kidney disease databas e in Japan.
Sci Rep 10(1) 7351 2020
Yokoyama H, Yamamo to R, Imai E, Maru yama S, Sugiyama H, Nitta K, Tsukamot o T, Uchida S, Tak eda A, Sato T, Wad a T, Hayashi H, Ak ai Y, Fukunaga M, Tsuruya K, Masutan i K, Konta T, Shoj i T, Hiramatsu T, Goto S, Tamai H, N ishio S, Shirasaki A, Nagai K, Yamaga ta K, Hasegawa H, Yasuda H, Ichida S, Naruse T, Fukami K, Nishino T, Soba jima H, Tanaka S, Akahori T, Ito T, Terada Y, Katafuch i R, Fujimoto S, O kada H, Ishimura E, Kazama JJ, Hiromu ra K, Mimura T, Su zuki S, Saka Y, So fue T, Suzuki Y, S hibagaki Y, Kitaga wa K, Morozumi K, Fujita Y, Mizutani M, Shigematsu T, F uruichi K, Fujimot o K, Kashihara N, Sato H, Matsuo S, Narita I, Isaka Y.
Better remission rates i n elderly Japanese patie nts with primary membran ous nephropathy in natio nwide real-world practic e: The Japan Nephrotic S yndrome Cohort Study (JN SCS).
Clin Exp Ne phrol
24(10) 893-909 2020
Takahashi-Kobayash i M, Usui J, Kanek o S, Sugiyama H, N itta K, Wada T, Mu so E, Arimura Y, M akino H, Matsuo S, Yamagata K.
Age-dependent survival i n rapidly progressive gl omerulonephritis: A nati onwide questionnaire sur vey from children to the elderly.
PLoS One 15(7) e0236017 2020
Wallace Z, Zhang Y, Perugino CA, Nade n R, Choi HK, Ston e JH, ACR/EULAR Ig G4 Classification Criteria Committe e. Clinical phenot ypes of IgG4-relat ed disease
An analysis of two inter national cross-sectional cohorts.
Annals Rheu m Dis
78(3) 406-412 2019
Nakamura T, Satoh- Nakamura T, Nakaji ma A, Kawanami T, Sakai T, Fujita Y, Iwao H, Miki M, Ma saki Y, Okazaki T, Ishigaki Y, Kawano M, Yamada K, Matsu i S, Saeki T, Kami sawa T, Yamamoto M, Hamano H, Origuch i T, Hirata S, Tan aka Y, Tsuboi H, S umida T, Okazaki K, Tanaka M, Chiba T, Mimori T, Umehara T
Impaired expression of i nnate immunityrelated ge nes in IgG4-related dise ase: A possible mechanis m in the pathogenesis of IgG4-RD.
Modern Rheu matol
11 1-7 2019
Terao C, Ota M, Iw asaki T, Shiokawa M, Kawaguchi S, Ku riyama K, Kawaguch i T, Kodama Y, Yam aguchi I, Uchida K, Higasa K, Yamamot o M, Kubota K, Yaz umi S, Hirano K, M asaki Y, Maguchi H, Origuchi T, Matsu i S, Nakazawa T, S hiomi H, Kamisawa T, Hasebe O, Iwasa ki E, Inui K, Tana ka Y, Ohshima K, A kamizu T, Nakamura S, Saeki T, Umehar a H, Shimosegawa T, Mizuno N, Kawano M, Azumi A, Takaha shi H, Mimori T, K amatani Y, Okazaki K, Chiba T, Kawa S, Matsuda F
IgG4-related disease in the Japanese population:
a genome-wide associatio n study.
Lancet Rheu matology
1(1) 14-22 2019
Niwamoto T, Handa T, Matsui S, Yamam oto H, Yoshifuji H, Abe H, Matsumoto H, Kodama Y, Chiba T, Seno H, Mimori T, Hirai
Phenotyping of IgG4-rela ted diseases based on af fected organ pattern: A multicenter cohort study using cluster analysis.
Modern Rheu matol
4 1-6 2020
Kakiuchi N, Yoshid a K, Uchino M, Kih ara T, Akaki K, I noue Y , Kawada K, Nagayama S, Yo koyama A, Yamamoto S, Matsuura M, H orimatsu T, Hirano T, Goto N, Takeu chi Y, Ochi Y, Sh iozawa Y, Kogure Y, Watatani Y, Fu jii Y, Kim SK, Kon A, Kataoka K, Yos hizato T, Nakagawa M, Yoda A, Nanya Y, Makishima H, Sh iraishi Y, Chiba K, Tanaka H, Sanad a M, Sugihara E, S ato T, Maruyama T, Miyoshi H, Take to MM, Oishi J, In agaki R, Ueda Y, O kamoto S, Okajima H, Sakai Y, Sakura i T, Haga H, Hirot a S, Ikeuchi H, Na kase H, Marusawa H, Chiba T, Takeuc hi O, Miyano S, Se no H, Ogawa
Frequent mutations that converge on the NFKBIZ p athway in ulcerative col itis.
Nature 577(7789) 260-265 2020
Zhu Y, Cui G, Miya uchi E, Nakanishi Y, Mukohira H, Shi mba A, Abe S, Tani -ichi S, Hara T, N akase H, Chiba T, Sehara-Fujisawa A, Seno H, Ohono H, Ikuta K.
Intestinal epithelial ce ll-derived IL-15 determi nes local maintenance an d maturation of intraepi thelial lymphocytes in t he intestine.
Int Immunol 32(5) 307-319 2020
Shiokawa M, Kodama Y, Chiba T
Different frequencies of antibody responses in Ig G4-related disease.
Arthritis R heuatol
72(9 1584-1585 2020
Sankoda N, Tanabe W, Tanaka A, Shiba ta H, Woltjen K, C hiba T, Haga H, Sa kai Y, Mandai M, Y amamoto T, Yamada Y, Uemoto S, Kawag uchi Y
Epithelial expression of Gata 4 and Sox2 regulate s specification of the s quamous-columnar junctio n via MAPK/ERK signaling in mice.
Nat Commun 12(1) 560 2021
Niwamoto T, Handa T, Matsui S, Yamam oto H, Yoshifuji H, Abe H, Matsumoto H, Kodama Y, Chiba T, Seno H, Mimori T, Hirai
Phenotyping of IgG4-rela ted diseases based on af fected organ pattern: A multicenter cohort study using cluster analysis.
Modern Rheu matol
31(1) 235-240 2021
Yamaguchi I, Furus awa Y, Kawaguchi T, Yagishita N, Tanz awa K, Yamano Y, M atsuda F
Establishment of a Compr ehensive Information Inf rastructure and a Suppor t Organization for Rare Disease Research in Japa n (RADDAR-J).
Stud Health Technol In form
264 1080-1083 2019
Hiroo Hoshina,Yoht a Shimada,Takashi Higuchi, Hiroshi K obayashi, Hiroyuki Ida, Toya Ohashi.
Chaperone effect of sulf ated disaccharide from h eparin on mutant idurona te-2-sulfatase in mucopo lysaccharidosis type Ⅱ
Molecular G enetics and Metabolis m
123 118-122 2018
Kobayashi M, Ohash i T, Kaneshiro E, Higuchi T, Ida H.
Mutation spectrum of α- galactosidase A gene in Japanese patients with F abry disease.
J Hum Gene t.
64 695-699 2019
Hiroyuki Ida Gaucher Disease． Human Patho biochemist ry eds.
57-66 2019
Nojiri A, Anan I, Morimoto S, Kawai M, Sakuma T, Kobay ashi M, Kobayashi H, Ida H, et al
Clinical findings of gad olinium-enhanced cardiac magnetic resonance in F abry patients.
J Cardiol. 75 27-33 2020
Miwa S, Watabe A, Shimada Y, Higuchi T, Kobayashi H, F ukuda T, Kato F, I da H, et al
Efficient engraftment of genetically modified cel ls is necessary to ameli orate central nervous sy stem involvement of muri ne model of mucopolysacc haridosis type II by hem atopoietic stem cell tar geted gene therapy.
Mol Genet M etab.
130 262-273 2020
Wada M, Shimada Y, Izuka S, IshiiN, H iraki H, Tachibana T, Maeda K, Saito M, Arakawa S, Ishi moto T, Ida H, et al
Ex vivo gene therapy tre ats bone complications o f mucopolysaccharidosis typeII mouse models thro ugh bone remodeling reac tivation.
Mol Ther Me thods Clin Dev.
19 261-274 2020
Kuwahara M, Suzuki H, Oka N, Ogata H, Yanagimoto S, Sada kane S, Fukumoto Y, Yamana M, Yuhara Y, Yoshikawa K, Mo rikawa M, Kawai S, Okazaki M, Tsujimo to T, Kira JI, Kus unoki S.
Electron microscopic abn ormality and therapeutic efficacy in chronic infl ammatory demyelinating p olyneuropathy with anti- neurofascin155 immunoglo bulin G4 antibody
Muscle Nerv e
57 498-502 2018
Miyamoto K, Fujiha ra K, Kira JI, Kur iyama N, Matsui M, Tamakoshi A, Kusun oki S.
Nationwide epidemiologic al study of neuromyeliti s optica in Japan.
J Neurol Ne urosurg Psy chiatry
89 667-668 2018
Yoshikawa K, Kuwah ara M, Morikawa M, Fukumoto Y, Yamana M, Yamagishi Y, Ku sunoki S.
Varied antibody reactivi ties and clinical releva nce in anti-GQ1b antibod y-related diseases.
Neurol Neur oimmunol Ne uroinflamm
5 e501 2018
Kuwahara M, Numoto I, Kusunoki S
Multifocal nodular hyper trophy of trigeminal ner ve in multifocal acquire d demyelinating sensory and motor neuropathy.
Neurol Neur oimmunol Ne uroinflamm
6 e553 2019
Hirano M, Isono C, Fukuda K, Ueno S, Nakamura Y, Kusuno ki S
Effects of the rotigotin e transdermal patch vers us oral levodopa on swal lowing in patients with Parkinson's disease
J Neurol Sc i
404 5-10 2019
Yoshikawa K, Kuwah ara M, Morikawa M, Kusunoki S.
Bickerstaff brainstem en cephalitis with or witho ut anti-GQ1b antibody.
Neurol Neur oimmunol Ne uroinflamm
7(6) e889 2020
Yamagishi Y, Kuwah ara M, Suzuki H, S onoo M, Kuwabara S, Yokota T, Nomura K, Chiba A, Kaji R, Kanda T, Kaida KI, Mutoh T, Yamasaki R, Takashima H, Ma tsui M, Nishiyama K, Sobue G, Kusuno ki S.
Serum IgG anti-GD1a anti body and mEGOS predict o utcome in Guillain-Barré syndrome.
J Neurol Ne urosurg Psy chiatry
91(12) 1339-1342 2020
Kusunoki S CSF sphingomyelin: possi ble biomarker of demyeli nation.
J Neurol Ne urosurg Psy chiatry.
92(3) 232 2021
Kusunoki S, Willis on HJ, Jacobs BC
Antiglycolipid antibodie s in Guillain-Barré and Fisher syndromes: discov ery, current status and future perspective
J Neurol Ne urosurg Psy chiatry
92(3) 311-318 2021
Watanabe M, Nishik awa H, Miyasaka N, Sato R, Sato D, Hayashi Y, Kondo T.
Adverse Drug Reaction Re lief System in Japan: Fr om Clinical Perspective
Ther Innov Regul Sci
J u l ; 5 4 (4):
731-737 2020
Hosoya T, Sugihara T, Miyasaka N, Yas uda S.
Novel treatment strategy of polymyalgia rheumatic a targetingdrug-free rem ission
Clin Exp Rh eumatol
PMID: 332 53104
2020
Kaneko Y, Kawahito Y, Kojima M, Nakay ama T, Hirata S, K ishimoto M, Endo H, Seto Y, Ito H, Ni shida K, Matsushit a I, Kojima T, Kam atani N, Tsutani K, Igarashi A, Haseg awa M, Miyasaka N, Yamanaka H.
Efficacy and safety of t acrolimus in patients wi th rheumatoid arthritis - A systematic review an d meta-analysis.
Mod Rheumat ol.
30 1-9. doi: 10.
1080/1439759 5.2020.17196 07. [Epub ah ead of print]
2020
Tanaka Y, Atsumi T, Yamamoto K, Takeu chi T, Yamanaka H, Ishiguro N, Eguchi K, Watanabe A, Ori gasa H, Shoji T, M iyasaka N, Koike T.
Factors associated with successful discontinuati on of certolizumab pegol in early rheumatoid arth ritis.
Int J Rheum Dis.
23(3) 316-324. do i: 10.1111/1 756-185X.137 80. Epub 202 0 Jan 19.
2020
Tanaka Y, Oba K, K oike T, Miyasaka N, Mimori T, Takeuch i T, Hirata S, Tan aka E, Yasuoka H, Kaneko Y, Murakami K, Koga T, Nakano K, Amano K, Ushio K, Atsumi T, Inoo M, Hatta K, Mizuki S, Nagaoka S, Tsun oda S, Dobashi H, Horie N, Sato N.
Sustained discontinuatio n of infliximab with a r aising-dose strategy aft er obtaining remission i n patients with rheumato id arthritis: the RRRR s tudy, a randomised contr olled trial.
Ann Rheum D is.
79(1) 94-102. doi:
10.1136/ann rheumdis-201 9-216169. Ep ub 2019 Oct 19.
2019
Kojima M, Nakayama T, Tsutani K, Igar ashi A, Kojima T, Suzuki S, Miyasaka N, Yamanaka H.
Epidemiological characte ristics of rheumatoid ar thritis in Japan: Preval ence estimates using a n ationwide population-bas ed questionnaire survey.
Mod Rheumat ol.
14 1-7. doi: 10.
1080/1439759 5.2019.16827 76. [Epub ah ead of print]
2019
Takada K, Katada Y, Ito S, Hayashi T, Kishi J, Itoh K, Y amashita H, Hiraka ta M, Kawahata K, Kawakami A, Watana be N, Atsumi T, Ta kasaki Y, Miyasaka N.
Impact of adding tacroli mus to initial treatment of interstitial pneumoni tis in polymyositis/derm atomyositis: a single-ar m clinical trial.
Rheumatolo g y ( Oxfo r d).
pii: kez3 94. doi:
10.1093/r heumatolo gy/kez39 4. [Epub ahead of print]
2019
Miyabe C, Miyabe Y, Nagai J, Miura NN, Ohno N, Chun J, T suboi R, Ueda H, M iyasaka M, Miyasak a N, Nanki T.
Abrogation of lysophosph atidic acid receptor 1 a meliorates murine vascul itis.
Arthritis R es Ther.
21(1) 191. doi: 10.
1186/s13075- 019-1973-0.
2019
Kato M, Kaneko Y, Tanaka Y, Inoo M, Kobayashi-Haraoka H, Amano K, Miyata M, Murakawa Y, Yas uoka H, Hirata S, Nagasawa H, Tanaka E, Miyasaka N, Yam anaka H, Yamamoto K, Yokota I, Atsum i T, Takeuchi T.
Predictive value of seru m amyloid a levels for r equirement of concomitan t methotrexate in tocili zumab initiation: A post hoc analysis of the SURP RISE study.
Mod Rheumat ol.
7 1-8. doi: 10.
1080/1439759 5.2019.16210 26. [Epub ah ead of print]
2019
Takeuchi T, Miyasa ka N, Pedersen R, Sugiyama N, Hirose T.
Radiographic and clinica l outcomes following eta nercept monotherapy in J apanese methotrexate-naï ve patients with active rheumatoid arthritis.
Mod Rheumat ol.
30(2) 259-268. do i: 10.1080/1 4397595.201 9.1589918. E pub 2019 Mar 29.
2019
Kasai S, Sakai R, Koike R, Kohsaka H, Miyasaka N, Harig ai M.
Higher risk of hospitali zed infection, cardiovas cular disease, and fract ure in patients with rhe umatoid arthritis determ ined using the Japanese health insurance databas e.
Mod Rheumat ol.
29(5) 788-794. do i: 10.1080/1 4397595.201 8.1519889. E pub 2018 Nov 28.
2019
Yamanaka H, Hirose T, Endo Y, Sugiyam a N, Fukuma Y, Mor ishima Y, Sugiyama N, Yoshii N, Miyas aka N, Koike T.
Three-year safety and tw o-year effectiveness of etanercept in patients w ith rheumatoid arthritis in Japan: Results of lon g-term postmarketing sur veillance.
Mod Rheumat ol.
29(5) 737-746. do i: 10.1080/1 4397595.201 8.1510759. E pub 2018 Sep 20.
2019
Kaneko Y,Kato M,Ta naka Y,InooM,Kobay ashi-Haraoka H, Am ano K,Miyata M, Mu rakawa,Y, Yasuoka H, Hirata S,Tanaka E, Miyasaka N, Ya manaka H,Yamamoto K, Takeuchi T, SUR PRISE study group
Tocilizumab discontinu ation after attaining re mission in patients with rheumatoid arthritis who were treated with tocili zumab alone or in combin ation with methotrexate:
results from a prospecti ve randomised controlled study (the second year o f the SURPRISE study)
Ann Rheum D is
Sep;77(9) 1268-1275 2018
Umezawa, N, Kwahat a K, Mizoguchi F, Kimura N, Yoshihas hi-Nakazato Y, Miy asaka N, Kohsaka H.
Interleukin-23 as a ther apeutic target for infla mmatory myopathy
Sci Rep A p r 3 ; 8 (1)
doi: 10.1038 /s41598-018- 23539-4.
2018
Wolfien M.et.al Hematopoietic stem-cell senescence and myocardia l repair - Coronary arte ry disease genotype/phen otype analysis of post-M I myocardial regeneratio n response induced by CA BG/CD133+ bone marrow he matopoietic stem cell tr eatment in RCT PERFECT P hase 3.
EBioMedici ne
57 102862 2020
Akiyama N, Shimura M, Yamazaki T, Har ashima H, Fushimi T, Tsuruoka T, Ebi hara T, Ichimoto K, Matsunaga A, Sait o-Tsuruoka M, Yats uka Y, Kishita Y, Kohda M, Namba A, Kamei Y, Okazaki Y, Kosugi A, Ohtake A, Murayama K
Prenatal diagnosis of severe mitochondrial diseases caused by nuclear gene defects:
a study in Japan.
Sci Rep 11(1) 3531 2021
Koshizaka M, Maeza wa Y, Maeda Y, Sho ji M, Kato H, Kane ko H, Ishikawa T, Kinoshita D, Kobay ashi K, Kawashima J, Sekiguchi A, Mo tegi SI, Nakagami H, Yamada Y, Tsuka moto S, Taniguchi A, Sugimoto K, Sho da Y, Hashimoto K, Yoshimura T, Suzuk i D, Kuzuya M, Tak emoto M, Yokote K.
Time gap between the ons et and diagnosis in Wern er syndrome: a nationwid e survey and the 2020 re gistry in Japan
Aging (Alba ny NY) .
12 24940-24956 2020
村山圭 ミトコンドリア病 特殊ミルク 治療ガイド ブック
24 71-73 2020
村山圭 先天代謝異常症 今日の診断 指針
第8版総 1918-1920 2020
村山圭 カルニチン回路異常症 新臨床内科 学
第10版第6 章
784-786 2020
杉山洋平、村山圭 新生児期に緊急対応が必要 な先天代謝異常症
新生児内分 泌ハンドブ ック
新版 7代 謝
213-225 2020
盛一享德 小児疾患の医療費助成制度 小児外科 53(3) 249-51 2021 盛一享德 小児慢性特定疾病と指定難
病
Modern Medi a
66(3) 68-73 2020
Nagasaka M, Yamagi shi M, Yagishita N, Araya N, Kobayash i S, Makiyama J, K ubokawa M, Yamauch i J, Hasegawa D, C oler-Reilly ALG, T sutsumi S, Uemura Y, Arai A, Takata A, Inoue E, Hasega wa Y, Watanabe T, Suzuki Y, Uchimaru K, Sato T, Yamano Y.
Mortality and risk of pr ogression to adult T-cel l leukemia/lymphoma in H TLV-1-associated myelopa thy/tropical spastic par aparesis.
Proc Natl A cad Sci U S A
117(21) 11685- 11691
2020
Yamauchi J, Araya N, Yagishita N, Sa ta t, Yamano Y.
An update on human T-cel l leukemia virus type I (HTLV-1)-associated myel opathy/tropical spastic paraparesis (HAM/TSP) fo cusing on clinical and l aboratory biomarkers.
Pharmacol T her
218 107669 2021
Yamakawa N, Yagish ita N, Matsuo T, Y amauchi J, Ueno T, Inoue E, Takata A, Nagasaka M, Araya N, Hasegawa D, Col er-Reilly A, Tsuts umi S, Sato T, Ara ujo A, Casseb J, G otuzzo E, Jacobson S, Martin F, Pucci oni-Sohler M, Tayl or GP, Yamano Y; J apan Clinical Rese arch Group on HAM/
TSP.
Creation and validation of a bladder dysfunction symptom score for HTLV-1 -associated myelopathy/t ropical spastic parapare sis.
Orphanet J Rare Dis
15(1) 175 2020
Kamoi K, Horiguchi N, Kurozumi-Karube H, Hamaguchi I, Y amano Y, Uchimaru K, Tojo A, Watanab e T, Ohno-mtsui K.
Horizontal transmission route responsible for hu man T-cell lymphotropic virus type 1 uveitis.
Lancet Infe ct Dis
in press 2021
Penova M, Kawaguch i S, Yasunaga J, K awaguchi T, Sato T, Takahashi M, Shim izu M, Saito M, Ts ukasaki K, Nakagaw a M, Takenouchi N , Hara H, Matsuura E, Nozuma S, Takas hima H, Izumo S, W atanabe T, Uchimar u K, Iwanaga M, Ut sunomiya A, Tabara Y, Paul R, Yamano Y, Matsuoka M, Mat suda F.
Genome wide association study of HTLV-1-associat ed myelopathy/tropical s pastic paraparesis in th e Japanese population.
Proc Natl A cad Sci USA
118(11) e2004199118 2021
Takeda R, Ishigaki T, Ohno N, Yokoyam a K, Kawamata T, F ukuyama T, Araya N, Yamano Y, Uchimar u K, Tojo A.
Immunophenotypic analysi s of cerebrospinal fluid reveals concurrent devel opment of ATL in the CNS of a HAM/TSP patient.
Int J Hemat ol
111(6) 891-896 2020
Hagiwara Y, Shimiz u T, Yanagisawa T, Akasu Y, Kaburagi K, Kikuchi T, Shib ata S, Matsumoto H, Soga K, Tsuchihas hi Y, Nagasaka M, Sasaki N, Maki F, Shiraishi M, Akiya ma H, Hasegawa Y, Yamano Y.
Utility of transoral mot ion-mode ultrasonography to detect tongue fascic ulation in patients with amyotrophic lateral scle rosis.
Muscle Nerv e
Online ah ead of pr int
2021
Araujo A, Bangham CRM, Casseb J, Got uzzo E, Jacobson S, Martin F, Penalva A, Puccioni-Sohler M, Taylor GP, Yam ano Y.
Management of HAM/TSP. s ystematic review and con sensus-based recommendat ions 2019.
Neurol Clin Pract
11(1) 49-56 2021
Okuma K, Kuramitsu M, Niwa T, Taniguc hi T, Masaki Y, Ue da G, Matsumoto C, Sobata R, Sagara Y, Nakamura H, Satak e M, Miura K, Fuch i N, Masuzaki H, O kayama A, Umeki K, Yamano Y, Sato T, Iwanaga M, Uchimar u K, Nakashima M, Utsunomiya A, Kubo ta R, Ishitsuka K, Hasegawa H, Sasaki D, Koh KR, Taki M, Nosaka K, Ogata M, Naruse I, Kaneko N, Okajima S, Tezuka K, Ikebe E, Matsuo ka S, Itabashi K, Saito S, Watanabe T, Hamaguchi I.
Establishment of a novel diagnostic test algorith m for human T-cell leuke mia virus type 1 infecti on with line immunoassay replacement of western b lotting: a collaborative study for performance ev aluation of diagnostic a ssays in Japan,
Retrovirol ogy
17 26 2020
Sakamoto H, Itonag a H, Sawayama Y, K ojima A, Chiwata M, Fujioka M, Kitano sono H, Horai M, M iyazaki T, Shirais hi H, Imaizumi Y, Yoshida S, Hata T, Yamano Y, Miyazaki Y.
Allogeneic Hematopoietic Stem Cell Transplantati on for Adult T-cell Leuk emia/Lymphoma with HTLV- 1-associated Myelopathy.
Int J Hemat ol
Online ah ead of pr int
2021
Soga K, Shimizu T, Hagiwara Y, Ogura H, Akiyama H, Yama uchi J, Sato T, Ha nzawa K, Hasegawa Y, Yamano Y.
Soleal vein dilatation i n the early-phase of hos pitalization is associat ed with a subsequent dev elopment of deep vein th rombosis in patients wit h acute stroke.
J Med Ultra son(2001)
48(1) 97-104 2021
Tsuchihashi Y, Shi mizu T, Akiyama H, Hagiwara Y, Soga K, Takao N, Uchino K, Yanagisawa T, Yam auchi J, Sato T, H asegawa Y, Yamano Y.
The Risk Factors for Dea th within 6 Months After Ischemic Stroke in Patie nts with Cancer.
J Stroke Ce rebrovasc D is
29(12) 105365 2020
Takao N, Hagiwara Y, Shimizu T, Soga K, Tsuchihashi Y, Otsubo H, Tatsuno K, Takaishi S, Usu ki N, Yoshie T, Ta kada T, Ueda T, Ha segawa Y, Yamano Y.
Preprocedural Carotid Pl aque Echolucency as a Pr edictor of In-Stent Inti mal Restenosis after Car otid Artery Stenting.
J Stroke Ce rebrovasc D is
29(12) 105339 2020
Shimizu J, Yamano Y, Kawahata K, Suz uki N.
Elucidation of predictor s of disease progression in patients with relapsi ng polychondritis at the onset: potential impact on patient monitoring.
BMC Rheumat ol
4 41 2020
Sakurai K, Shinoha ra K, Imai T, Yama no Y, Hasegawa Y.
A Case of Severe Multipl e Sclerosis Manifesting upon GnRH Agonist Therap y for Uterine Fibroids:
A Case Report.
Intern Med 59(23) 3093-3096 2020
山野嘉久. HTLV-1関連脊髄症（HAM）に 対する分子標的治療薬.
脳神経疾患 最新の治 療
2021-2023 32-34 2021
山野嘉久. HTLV-1関連脊髄症（HAM)の 研究進展からみえる診療の 未来像.
SRL宝函 41(3) 21-30 2020
山野嘉久. HAM/TSPの診断指針 HTLV- 1関連脊髄症（HAM)診察ガイ ドライン2019を踏まえて.
脊柱脊髄ジ ャーナル
33(4) 498-503 2020
佐 藤 知 雄, 山 野 嘉 久.
免疫性神経疾患 update ― 基礎・臨床研究の最新知見
― HAMに対する治療薬の現 況と展望.
日本臨床 78(11) 1939-1944 2020
新谷奈津美, 山野嘉 久.
HTLV-1関連脊髄症（HAM）の 病態.
別冊BIO Cli nica 神経疾 患と慢性炎 症
9(2) 29-33 2020
山 内 淳 司, 山 野 嘉 久, 湯沢賢治.
臓器移植におけるHTLV-1感 染への対応.
日本臨床腎 移植学会雑 誌
8(1) 42-51 2020
山 内 淳 司, 山 野 嘉 久.
HTLV-1関連脊髄症（HAM)の 発症メカニズム.
周産期医学 50(10) 1695-1698 2020
山 内 淳 司, 山 野 嘉 久.
HTLV-1関連脊髄症. CLINICAL NE UROSCIENCE
38(10) 1270-1271 2020
八木下尚子、山野嘉 久.
HTLV-1関連脊髄症. 生体の科学 71(5) 422-423 2020
鈴木祐, 秋山久尚, 星野俊, 鹿島悟, 原 大祐, 土橋瑶子, 伊 佐 早 健 司, 櫻 井 謙 三, 眞木二葉, 長谷 川泰弘, 山野嘉久.
院内発症脳卒中の診断・治 療遅延因子.
脳卒中 in press 2020
曽 我 海 馬, 清 水 高 弘, 飯島直樹, 鷹尾 直誠, 土橋瑶子, 柴 田宗一郎, 小倉英, 萩 原 悠 太, 桒 田 千 尋, 佐々木直, 秋山 久尚, 長谷川泰弘, 山野嘉久.
頸動脈狭窄患者において血 清MMP-9濃度は頭蓋内主幹 動 脈 狭窄 リス クと 関連す る.
聖マリアン ナ医科大学 雑誌
48(3) 101-108 2020
鷹 尾 直 誠, 櫻 井 謙 三, 日野栄絵, 山野 嘉久.
再発性細菌性髄膜炎の原因 として鼻汁を契機に鼻性髄 液漏の診断に至った1例.
臨床神経 61(3) 177-181 2021
萩 原 悠 太, 菊 池 崇 之, 赤須友香利, 松 本博文, 鏑木圭, 柴 田宗一郎，笹野恭之,
齋藤善光, 清水高
弘, 山野嘉久.
扁桃周囲膿瘍に対する経口 腔咽頭超音波ガイド下排膿 穿刺術―経口腔頸動脈超音 波の応用―.
Neurosonol ogy
33(2) 45-49 2020
Yamauchi J, Sato T, Yagishita N, Aray a N, Hasegawa D, T sutsumi S, Nagasak a M, Coler-Reilly A, Inoue E, Takata A, Hasegawa Y, Yam ano Y.
Use of cerebrospinal flu id CXCL10 and neopterin as biomarkers in HTLV-1- associated myelopathy/tr opical spastic parapares is treated with steroids.
J Neurol Ne urosurg Psy chiatry
91(3) 321-323 2020
Tsutsumi S, Sato T, Yagishita N, Yama uchi J, Araya N, H asegawa D, Nagasak a M, Coler-Reilly A, Inoue E, Takata A, Yamano Y.
Real-World Clinical Cour se of HTLV-1-Associated Myelopathy/Tropical Spas tic Paraparesis (HAM/TSP) in Japan.
Orphanet Jo urnal of Ra re Diseases
14(1) 227 2019
Katsuya H, Islam S, Tan BJY, Ito J, M iyazato P, Matsuo M, Inada Y, Iwase SC, Uchiyama Y, Ha ta H, Sato T, Yagi shita N, Araya N, Ueno T, Nosaka K, Tokunaga M, Yamagi shi M, Watanabe T, Uchimaru K, Fujisa wa JI, Utsunomiya A, Yamano Y, Satou Y.
The Nature of the HTLV-1 Provirus in Naturally In fected Individuals Analy zed by the Viral DNA-Cap ture-Seq Approach.
Cell Rep 29(3) 724-735.e4 2019
Tamaki K, Sato T, Tsugawa J, Fujioka S, Yagishita N, Ar aya N, Yamauchi J, Coler-Reilly A, Na gasaka M, Hasegawa Y, Yamano Y, Tsubo i Y.
Cerebrospinal Fluid CXCL 10 as a Candidate Surrog ate Marker for HTLV-1-As sociated Myelopathy/Trop ical Spastic Paraparesis.
Front Micro biol
10 2110 2019
Yamaguchi I, Furus awa Y, Kawaguchi T, Yagishita N, Tanz awa K, Yamano Y, M atsuda F.
Establishment of a Compr ehensive Information Inf rastructure and a Suppor t Organization for Rare Disease Research in Japa n (RADDAR-J).
Stud Health Technol In form
264 1080-1083 2019
山 内 淳 司, 山 野 嘉 久, 湯沢賢治.
腎移植におけるHTLV-1感染 のリスク.
移植 54(6) 305-307 2019
山内淳司、山野嘉久. HAMの病態とHTLV-1感染細 胞の異常.
細胞 51(10) 20-23 2019
山野嘉久. HTLV-1. 産科と婦人 科 増刊号
87 25-28 2020
八木下尚子、山野嘉 久.
患者レジストリの分類. 脳神経内科 92(3) 271-275 2020
Sato T, Coler-Reil ly ALG, Yagishita N, Araya N, Inoue E, Furuta R, Watan abe T, Uchimaru K, Matsuoka M, Matsum oto N, Hasegawa Y, Yamano Y.
Mogamulizumab (Anti-CCR 4) in HTLV-1-Associated Myelopathy.
N Engl J Me d
378(6) 529-538 2018
Yamauchi J, Yamano Y, Yuzawa K.
Risk of Human T-cell Leu kemia Virus Type 1 Infec tion in Kidney Transplan tation.
N Engl J Me d
380(3) 296-298 2019
Sato T, Yagishita N, Tamaki K, Inoue E, Hasegawa D, Nag asaka M, Suzuki H, Araya N,Coler-Reil ly AL, Hasegawa Y, Tsuboi Y, Takata A, Yamano Y.
Proposal of Classificati on Criteria for HTLV-1-A ssociated Myelopathy/Tro pical Spastic Paraparesi s Disease Activity.
Front Micro biol
9 1651 2018
Furusawa Y, Yamagu chi I, Yagishita N, Tanzawa K, Matsud a F, Yamano Y, RAD DAR‐J Research an d Development Grou p.
National platform for Ra re Diseases Data Registr y of Japan.
Learning He alth System s
e10080 2019
Oka T, Mizuno H, S akata M, Fujita H, Yoshino T, Yamano Y, Utsumi K, Masuj ima T, Utsunomiya A.
Metabolic abnormalities in adult T-cell leukemia /lymphoma and induction of specific leukemic cel l death using photodynam ic therapy.
Sci Rep 8(1) 14979 2018
Kuramitsu M, Okuma K, Nakashima M, Sa to T, Sasaki D, Ha segawa H, Umeki K, Kubota R, Sasada K, Sobata R, Matsumo to C, Kaneko N, Te zuka K, Matsuoka S, Utsunomiya A, Koh KR, Ogata M, Ishit suka K, Taki M, No saka K, Uchimaru K, Iwanaga M, Sagara Y, Yamano Y, Okaya ma A, Miura K, Sat ake M, Saito S, Wa tanabe T, Hamaguch i I.
Development of reference material with assigned v alue for human T-cell le ukemia virus type 1 quan titative PCR in Japan.
Microbiol I mmunol
62(10) 673-676 2018
Kawano N, Yoshida S, Kawano S, Kuriy ama T, Tahara Y, T oyofuku A, Manabe T, Doi A, Terasaka S, Yamashita K, Ue da Y, Ochiai H, Ma rutsuka K, Yamano Y, Shimoda K, Kiku chi I.
The clinical impact of h uman T-lymphotrophic vir us type 1 (HTLV-1) infec tion on the development of adult T-cell leukemia -lymphoma (ATL) or HTLV- 1– associated myelopathy (HAM) / atypical HAM af ter allogeneic hematopoi etic stem cell transplan tation (allo-HSCT) and r enal transplantation: 11 years of experience.
J Clin Exp Hematop
58(3) 107-121 2018
Shimizu J, Yamano Y, Kawahata K, Suz uki N.
Relapsing polychondritis patients were divided i nto three subgroups: pat ients with respiratory i nvolvement (R subgroup), patients with auricular involvement (A subgroup), and overlapping patient s with both involvements (O subgroup), and each g roup had distinctive cli nical characteristics.
Medicine 97(42) e12837 2018
Morio Y, Izawa KP, Omori Y, Katata H, Ishiyama D, Koyama S and Yamano Y.
The relationship between walking speed and step l ength in older aged pati ents.
Diseases. 7(1) 7 2019
Hirano M, Jimbo K, Ogawa M, Ochi K, M akiyama J, Kawamat a T, Yokoyama K, T anaka T, Inamoto Y, Yamano Y, Fukuda T, Uchimaru K, Ima i Y, Tojo A.
Chronic inflammatory dem yelinating polyneuropath y in adult T-cell leukem ia-lymphoma patients fol lowing allogeneic stem c ell transplantation Bone Marrow Transplantation.
Bone Marrow Transplan tation
53 1470– 1473 2018
Sato T, Yamano Y. Targeting human T‐lymph otropic virus type 1‐in fected cells with an ant i‐C‐C chemokine recept or 4 antibody in T‐lymp hotropic virus type 1‐a ssociated myelopathy.
Clin Exp Ne uroimmunol
9(3) 153-154 2018
八木下尚子, 山野嘉 久.
希少難病HAMの患者レジス トリを活用した治療薬開発 への取り組みと展望.
Jpn Pharmac ol Ther（薬 理と治療）
46(7) 1113-1116 2018
森 尾 裕 志, 大 森 圭 貢, 井澤和大, 堅田 紘頌, 石山大介, 小 山真吾, 中尾陽光, 山野嘉久.
高齢入院患者におけるペッ トボトルの開栓に必要な握 力.
専門リハビ リ
17 30-35 2018
Koshizaka M, Maeza wa Y, Maeda Y, Sho ji M, Kato H, Kane ko H, Ishikawa T, Kinoshita D, Kobay ashi K, Kawashima J, Sekiguchi A, Mo tegi SI, Nakagami H, Yamada Y, Tsuka moto S, Taniguchi A, Sugimoto K, Sho da Y, Hashimoto K, Yoshimura T, Suzuk i D, Kuzuya M, Tak emoto M, Yokote K.
Time gap between the ons et and diagnosis in Wern er syndrome: a nationwid e survey and the 2020 re gistry in Japan
Aging (Alba ny NY) .
12 24940-24956 2020
Shibata Y, Yabe I, Matsushima M, Hash imoto N, Yamada T, Sasaki H.
Investigating the role o f genetic counseling in neuromuscular disease co nsidering life events
J Hum Genet 64(6) 551-559 2019
佐々木秀直、水澤英 洋
国際コンセンサス基準とそ の問題点
Clinical Ne uroscience
37(9) 1110-1112 2019
佐々木秀直、運動失 調症の医療基盤に関 する調査研究班MSA 分科会
わが国の指定難病の診断基 準(案)- 現行基準の課題と 展望
Clincal Neu roscience
37(9) 1113-1116 2019
Uwatoko H, Hama Y, Iwata IT, Shirai S, Matsushima M, Yab e I, Utsumi J, Sas aki H.
Identification of plasma microRNA expression chan ges in multiple system a trophy and Parkinson's d isease
Mol Brain 12(1) e49 2019
Naganuma R, Yabe I, Takeuchi M, Moris hita K, Nakane S, Takase R, Takahash i-Iwata I, Matsush ima M, Otsuki M, S hiraishi H, Sasaki H.
Clinical factors affecti ng evoked magnetic field s in patients with Parki nson's disease
Plos One 15(9) e0232808 2020
Eguchi K, Tsuzaka K, Yabe I, Sasaki H.
Reversible splenial lesi on in new-onset refracto ry status epilepticus: A case report
Clin Neurol Neurosurg
183 105392 2019
Shirai S, Yabe I, Takahashi-Iwata I, Matsushima M, Ito YM, Takakusaki K, S asaki H.
The responsiveness of tr iaxial accelerometer mea surement of gait ataxia is higher than that of t he scale for the assessm ent and rating of ataxia in the early stages of s pinocerebellar degenerat ion
Cerebellum 18(4) 721-730 2019
野村 太一, 大嶌 祐 貴, 芳野 正修, 松 島 理明, 矢部 一 郎, 佐々木 秀直
高齢発症で家族歴の明らか ではない遺伝性トランスサ イレチン型アミロイドポリ ニューロパチーの2例
臨床神経 60(10) 688-692 2020
Yoshii K, Takahash i-Iwata I, Shirai S, Kobayashi S, Ya be I, Sasaki H.
A retrospective epidemio logical study of tick-bo rne encephalitis virus i n patients with neurolog ical disorders in Hokkai do, Japan
Microorgan isms
8(11) 1672 2020
Takahashi-Iwata I, Yabe I, Kudo A, Eguchi K, Wakita M, Shirai S, Matsush ima M, Toyoshima T, Chiba S, Tanikawa S, Tanaka S, Satoh K, Kitamoto T, Sas aki H.
MM2 cortical form of spo radic Creutzfeldt-Jakob disease without progress ive dementia and akineti c mutism: A case deviati ng from current diagnost ic criteria
J Neurol Sc i
412 116759 2020
佐藤智香、加納崇裕、
矢部一郎、佐々木秀 直
免疫療法が奏効した小細胞 肺癌合併抗CV2/CRMP5抗体 陽性脊髄症の1例
臨床神経 60(8) 560-564 2020
Iwata Y, Kitajima S, Yamahana J, Shi momura S, Yoneda-N akagawa S, Sakai N, Furuichi K, Ogura H, Sato K, Toyama T, Yamamura Y, Miy agawa T, Hara A, S himizu M, Ohkawa R, Kurano M, Yatomi Y, Wada T.
Higher serum levels of a utotaxin and phosphatidy lserine-specific phospho lipase A 1 in patients w ith lupus nephritis.
Int J Rheum Dis
24(2) 231-239 2020
Tran TTT, Hara A, Kitagawa K, Kitaji ma S, Toyama T, Iw ata Y, Sakai N, Sh imizu M, Kaneko S, Furuichi K, Wada T.
Relationship between aut oantibodies to erythropo ietin receptor and renal outcome in patients with anti-neutrophil cytoplas mic antibody-associated vasculitis
Biomarkers 25(2) 194-200 2020
Nagasaka K, Hariga i M, Hagino N, Har a A, Horita T, Hay ashi T, Itabashi M, Ito S, Katsumata Y, Kawashima S, Na niwa T, Sada KE, N ango E, Nakayama T, Tsutsumino M, Yam agata K, Homma S, Arimura Y.
Systematic review and me ta-analysis for 2017 cli nical practice guideline s of the Japan research committee of the ministr y of health, labour, and welfare for intractable vasculitis for the manag ement of ANCA-associated vasculitis
Mod Rheumat ol
29(1) 119-129 2019
Hara A, Wada T, Sa da KE, Amano K, Do bashi H, Harigai M, Takasaki Y, Yamad a H, Hasegawa H, H ayashi T, Fujimoto S, Muso E, Kawakam i T, Homma S, Yosh ida M, Hirahashi J, Ogawa N, Ito S, M akino H, Arimura Y;
Research Committe e on Intractable V asculitides, and t he Strategic Study Group to Establish the Evidence for I ntractable Vasculi tis Guideline.
Risk Factors for Relapse of Antineutrophil Cytopl asmic Antibody-associate d Vasculitis in Japan: A Nationwide, Prospective Cohort Study
J Rheumatol 45(4) 521-528 2018
